Today: 2 July 2026
Browse Category

EPA:LR.PA 2 July 2025

Edge Computing Global News & Trends Roundup (June–July 2025)

Edge Computing Global News & Trends Roundup (June–July 2025)

Coverage: This report highlights global developments in edge computing from June 1, 2025 through early July 2025, including regional news, industry-specific trends, market forecasts, and expert insights. North America: Edge computing momentum in North America remained strong. U.S. telecom operators rolled out new 5G multi-access edge computing services. For example, Verizon Business launched an Edge Transportation Exchange – a V2X platform leveraging 5G and mobile edge computing for real-time data sharing between vehicles, infrastructure, and pedestrians edgeir.com. The platform enables road safety use cases without expensive roadside units by using a virtualized edge architecture edgeir.com. Key deployments are underway with partners like Volkswagen, state transportation departments and universities to improve connected traffic systems. As Verizon’s VP Shamik Basu noted, “Cars are evolving from mechanical vehicles to software-defined mobile devices… Edge [technology] gives automakers, governments, and developers a robust platform for the cellular-connected future of transportation” edgeir.com. In industrial tech, Rockwell Automation introduced OptixEdge, an advanced gateway to process factory machine data on-site. By doing so, it reduces reliance on cloud servers and improves efficiency for smart manufacturing operations edgeir.com. According to Rockwell’s latest report, today’s smart machines generate massive data yet only 44% of it is used effectively – a

Stock Market Today

  • Cramer Sees Moderna's Pipeline Opening Up Beyond Covid
    July 1, 2026, 7:50 PM EDT. CNBC's Jim Cramer said on Mad Money that Moderna now looks different than during the Covid rush, with a cancer pipeline and vaccines reaching outside infectious diseases. He sees many programs still years out but calls for buying pullbacks, pointing to Moderna's track to profits and new data from late-stage cancer trials-like the melanoma combo trial with Merck's Keytruda. Moderna shares have jumped almost 150% this year but still trade under pandemic highs. Cramer also mentions fresh regulatory wins, including FDA advisory backing for its flu shot and a European nod for its combined Covid-flu vaccine.
Go toTop